CRP and Arthritis: For this purpose, the initial treatment target focuses on the absence of fever and marked reduction in CRP (by at least 50%) and the interim target includes the physician global assessment and the count of joints with active arthritis and/or the juvenile arthritis disease activity score (JADAS)-10 which has been validated for different categories of JIA, including SJIA [34].